Elisabet CuyÃ s

List of Publications by Year
in descending order

77	2,738	31	48
papers	citations	h-index	g-index
		147801	206112

78	78	78	4946
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 2022, 15, 19.	3.8	2
2	Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer. Cancers, 2021, 13, 1132.	3.7	22
3	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 2021, 14, 559.	3.8	14
4	Metformin Is a Pyridoxal-5â€²-phosphate (PLP)-Competitive Inhibitor of SHMT2. Cancers, 2021, 13, 4009.	3.7	15
5	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers, 2021, 13, 4168.	3.7	8
6	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death and Disease, 2021, 12, 977.	6.3	33
7	Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7737.	4.1	6
8	Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7661.	4.1	19
9	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	3.7	17
10	Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology. Frontiers in Oncology, 2020, 10, 620641.	2.8	5
11	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	3.1	99
12	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging, 2020, 12, 4794-4814.	3.1	38
13	Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer. Aging, 2020, 12, 24671-24692.	3.1	6
14	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. Aging, 2020, 12, 21057-21075.	3.1	2
15	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. Nutrients, 2019, 11, 1656.	4.1	26
16	Revisiting silibinin as a novobiocin-like Hsp90â€¯C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology, 2019, 132, 110645.	3.6	16
17	Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. OncoImmunology, 2019, 8, e1633235.	4.6	70
18	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. Food and Chemical Toxicology, 2019, 131, 110529.	3.6	15

#	Article	IF	Citations
19	A multiscale model of epigenetic heterogeneity-driven cell fate decision-making. PLoS Computational Biology, 2019, 15, e1006592.	3.2	28
20	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food and Chemical Toxicology, 2019, 128, 35-45.	3.6	27
21	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	4.1	32
22	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. Journal of Clinical Medicine, 2019, 8, 2180.	2.4	12
23	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	2.8	14
24	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. Aging, 2019, 11, 2874-2888.	3.1	25
25	In silico clinical trials for anti-aging therapies. Aging, 2019, 11, 6591-6601.	3.1	3
26	Silibinin is a direct inhibitor of STAT3. Food and Chemical Toxicology, 2018, 116, 161-172.	3.6	52
27	Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells. Carcinogenesis, 2018, 39, 601-613.	2.8	53
28	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	3.5	85
29	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell, 2018, 17, e12772.	6.7	58
30	Mitostemness. Cell Cycle, 2018, 17, 918-926.	2.6	15
31	Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model. PLoS Computational Biology, 2018, 14, e1006052.	3.2	23
32	Metformin inhibits <i>RANKL</i> and sensitizes cancer stem cells to denosumab. Cell Cycle, 2017, 16, 1022-1028.	2.6	19
33	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncology Reports, 2017, 38, 263-270.	2.6	11
34	Metformin Potentiates the Benefits of Dietary Restraint: A Metabolomic Study. International Journal of Molecular Sciences, 2017, 18, 2263.	4.1	18
35	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	1.8	9
36	Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histology and Histopathology, 2017, 32, 687-698.	0.7	40

#	Article	IF	Citations
37	<i>BRCA1</i> haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	1.8	12
38	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget, 2016, 7, 32006-32014.	1.8	47
39	Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges. Food and Chemical Toxicology, 2016, 96, 191-204.	3.6	27
40	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in <i>ALK</i>-rearranged lung cancer. Cell Cycle, 2016, 15, 3413-3418.	2.6	49
41	Metformin targets histone acetylation in cancer-prone epithelial cells. Cell Cycle, 2016, 15, 3355-3361.	2.6	17
42	Oncometabolic Nuclear Reprogramming of Cancer Stemness. Stem Cell Reports, 2016, 6, 273-283.	4.8	34
43	Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method. Journal of the American Society for Mass Spectrometry, 2016, 27, 168-177.	2.8	35
44	Mitophagy-driven mitochondrial rejuvenation regulates stem cell fate. Aging, 2016, 8, 1330-1352.	3.1	70
45	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience, 2016, 2, 958-967.	2.2	30
46	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in <i>NRAS</i>-mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	1.8	16
47	Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. Oncotarget, 2016, 7, 11959-11971.	1.8	9
48	Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. Oncotarget, 2016, 7, 71151-71168.	1.8	40
49	Germline <i>BRCA1</i> mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based â€œstarvationâ€•strategies in <i>BRCA1</i> carriers. Oncotarget, 2016, 7, 52974-52992.	1.8	26
50	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget, 2015, 6, 32317-32338.	1.8	35
51	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle, 2015, 14, 3527-3532.	2.6	25
52	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	1.8	53
53	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle, 2014, 13, 1132-1144.	2.6	57
54	Xenopatients 2.0: Reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle, 2014, 13, 358-370.	2.6	14

#	Article	IF	Citations
55	Cell Cycle Regulation by the Nutrient-Sensing Mammalian Target of Rapamycin (mTOR) Pathway. Methods in Molecular Biology, 2014, 1170, 113-144.	0.9	108
56	Active transmembrane drug transport in microgravity: a validation study using an ABC transporter model. F1000Research, 2014, 3, 201.	1.6	10
57	Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience, 2014, 1, 803-806.	2.2	31
58	Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics. Oncotarget, 2014, 5, 1942-1954.	1.8	14
59	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 2014, 5, 2344-2348.	1.8	40
60	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget, 2014, 5, 8306-8316.	1.8	94
61	The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget, 2014, 5, 3970-3982.	1.8	61
62	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. Anticancer Research, 2014, 34, 4323-7.	1.1	21
63	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	3.6	53
64	The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle, 2013, 12, 1166-1179.	2.6	146
65	The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer. Scientific Reports, 2013, 3, 2469.	3.3	97
66	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Scientific Reports, 2013, 3, 2560.	3.3	74
67	Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle, 2013, 12, 3471-3477.	2.6	37
68	Stem cell-like ALDH^{bright}cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	2.6	65
69	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Scientific Reports, 2013, 3, 2459.	3.3	67
70	Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle, 2013, 12, 3109-3124.	2.6	90
71	Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget, 2013, 4, 1484-1495.	1.8	31
72	Genetics of Ecstasy (MDMA) Use. , 2013, , 441-451.		1

#	Article	IF	Citations
73	The Influence of Genetic and Environmental Factors among MDMA Users in Cognitive Performance. PLoS ONE, 2011, 6, e27206.	2.5	38
74	GENETIC STUDY: 5â€HTTLPR polymorphism, mood disorders and MDMA use in a 3â€year followâ€up study. Addiction Biology, 2010, 15, 15-22.	2.6	31
75	The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users. Journal of Psychopharmacology, 2010, 24, 1381-1393.	4.0	17
76	Neurotoxic Thioether Adducts of 3,4-Methylenedioxymethamphetamine Identified in Human Urine After Ecstasy Ingestion. Drug Metabolism and Disposition, 2009, 37, 1448-1455.	3.3	30
77	The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans. Journal of Clinical Psychopharmacology, 2008, 28, 523-529.	1.4	49